Chemical Structure : Ladarixin sodium
CAS No.:
865625-56-5
Ladarixin sodium
(DF-2156; DF-2156A)
Catalog No.: PC-61475Not For Human Use, Lab Use Only.
A novel allosteric, noncompetitive dual CXCR1/2 inhibitor that inhibits human polymorphonuclear leukocyte (PMN) migration to CXCL8 in vitro with IC50 of 0.7 nM.
Bulk size, bulk discount!
E-mail: sales@probechem.com
Tech Support: tech@probechem.com
Purity & Documentation Purity:
>98% (HPLC)
Biological Activity
A novel allosteric, noncompetitive dual CXCR1/2 inhibitor that inhibits human polymorphonuclear leukocyte (PMN) migration to CXCL8 in vitro with IC50 of 0.7 nM; prevents PMN infiltration and tissue damage in several models of IR injury in vivo; abrogates motility and induces apoptosis in cultured cutaneous and uveal melanoma cells and xenografts; also prevents inflammation-mediated damage in MLD-STZ, prevents and reverses diabetes in NOD mice.
Diabetes
Phase 2 Clinical
Physicochemical Properties
|
M.Wt
|
397.315
|
|
Formula
|
C11H11F3NNaO6S2
|
|
Appearance
|
Solid
|
|
CAS No.
|
|
|
Storage
|
- Solide Powder
-
-20 °C 12 Months; 4°C 6 Months
|
- In Solvent
-
-80 °C 6 Months; -20°C 6 Months
|
|
Shipping
|
|
|
Solubility
|
10 mM in DMSO
|
|
Chemical Name/SMILES
|
4-((2R)-1-Oxo-1-(methanesulfonamido)propan-2-yl)phenyl trifluoromethanesulfonate sodium salt
|
References
1. Garau A, et al. Eur Cytokine Netw. 2006 Mar;17(1):35-41.
2. Citro A, et al. Diabetes. 2015 Apr;64(4):1329-40.
3. Kemp DM, et al. Oncotarget. 2017 Feb 28;8(9):14428-14442.
4. Bertini R, et al. Br J Pharmacol. 2012 Jan;165(2):436-54.
Contact Us
sales@probechem.com
